Results 211 to 220 of about 5,657,828 (286)

Estimating the critical points of an epidemic: An application of non-epidemiological logistic growth model for COVID-19

, 2020
Allaman IB, Jelihovschi EG.
europepmc   +1 more source

Discussion on critical points for a tailored therapy to cure hepatitis C virus infection. [PDF]

Clin Mol Hepatol, 2019
Marascio N, Quirino A, Barreca GS, Galati L, Costa C, Pisani V, Mazzitelli M, Matera G, Liberto MC, Focà A, Torti C.   +10 more
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Expected Number and Height Distribution of Critical Points of Smooth Isotropic Gaussian Random Fields. [PDF]

Bernoulli (Andover), 2018
Cheng D, Schwartzman A.
europepmc   +1 more source

Checkpoint blockade and the stem‐like T cell trade‐off

Molecular Oncology, EarlyView.
Stem‐like T cells are key to the success of programmed cell death protein 1 (PD1) blockade, as they sustain long‐term anti‐tumor response by continuously generating effector CD8+ T cells. However, how these cells are maintained in cancer is not fully understood. Hor et al.
Julie M. Mazet, Johanna A. Joyce
wiley   +1 more source

Critical Points and Traveling Wave in Locomotion: Experimental Evidence and Some Theoretical Considerations. [PDF]

Front Neural Circuits, 2017
Saltiel P, d'Avella A, Tresch MC, Wyler K, Bizzi E.   +4 more
europepmc   +1 more source

Molecular cancer prevention: Intercepting disease

Molecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco, Tej Pandya, Charles Swanton   +2 more
wiley   +1 more source

Critical Points for Interpreting Patients' Survival Rate Using Cancer Registries: A Literature Review. [PDF]

J Epidemiol, 2018
Okuyama A, Shibata A, Nishimoto H.
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Impact and Beneficial Critical Points of Clinical Outcome in Corticosteroid Management of Adult Patients With Sepsis: Meta-Analysis and GRADE Assessment. [PDF]

Front Pharmacol, 2019
Lin LL, Gu HY, Luo J, Wang L, Zhang C, Niu YM, Zuo HX.   +6 more
europepmc   +1 more source